Health Highlights: Nov. 1, 2008

Here are some of the latest health and medical news developments, compiled by editors ofHealthDay:

FDA OKs New Drug for Overactive Bladder

The U.S. Food and Drug Administration on Friday approved a new drug to help people who struggle with an overactive bladder.

The drug, Toviaz (fesoterodine fumarate), made by German manufacturer Schwarz Pharma, works by relaxing the smooth muscle tissue of the bladder, reducing frequent urination, the urge to urinate, and sudden urinary incontinence, theAssociated Pressreported.

"Patients who suffer from overactive bladder face quality of life issues that can hamper their ability to enjoy life to its fullest," Dr. George Benson, deputy director of the FDA's Division of Reproductive and Urologic Products, said in a news release. "This new drug will provide an additional treatment option to help them manage problems with an overactive bladder."

Toviaz, to be taken once a day by adults only, will be available by prescription only.

The FDA said it approved Toviaz based on the results of two studies involving more than 1,000 people with the disorder. Common side effects were dry mouth and constipation; less frequently reported side effects were dry eyes and trouble emptying the bladder, theAPsaid.

-----

Consumer Group Questions Safety of Nanoparticles in Sunscreens

Four out of five mineral-based sunscreens that claim not to contain nanoparticles actually do contain them, says a report released Friday by Consumers Union, publisher ofConsumer Reports.

The organization urged the U.S. Food and Drug Administration to conduct a full-scale safety review of nanoparticles in sunscreens.

"The widespread use of nanoparticles of titanium dioxide and zinc oxide in sunscreen is involving consumers in a vast experiment as to the safety of these products," Michael Hansen, a senior scientist at Consumers Union, said in a news release.